Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00580333
Recruitment Status : Completed
First Posted : December 24, 2007
Results First Posted : March 31, 2017
Last Update Posted : May 26, 2021
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Genentech, Inc.
Information provided by (Responsible Party):
Steven J Isakoff, MD, PhD, Massachusetts General Hospital

Tracking Information
First Submitted Date  ICMJE December 20, 2007
First Posted Date  ICMJE December 24, 2007
Results First Submitted Date  ICMJE April 2, 2014
Results First Posted Date  ICMJE March 31, 2017
Last Update Posted Date May 26, 2021
Study Start Date  ICMJE September 2007
Actual Primary Completion Date December 2010   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 22, 2017)
Pathologic Complete Response Rate After Preoperative Therapy With Cisplatin and Bevacizumab in ER-, PR-, Human Epidermal Growth Factor Receptor 2 (HER2) -Negative Early Breast Cancer. [ Time Frame: 2 years ]
The goal of this measure was to determine the pathologic complete response rate (Miller-Payne (MP) score 5) after preoperative therapy with cisplatin and bevacizumab in ER-, PR-, HER2-negative early breast cancer.
Original Primary Outcome Measures  ICMJE
 (submitted: December 20, 2007)
To determine the pathologic complete response rate after preoperative therapy with cisplatin and bevacizumab in ER-, PR-, HER2-negative early breast cancer. [ Time Frame: 2 years ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 22, 2017)
  • Clinical Overall and Complete Response Rates After Preoperative Therapy With Cisplatin and Bevacizumab [ Time Frame: 2 years ]
    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
  • Toxicity of Administering Bevacizumab in Combination With Standard Adjuvant Chemotherapy. [ Time Frame: 2 years ]
    Number of patients who were unable to receive all cycles of chemotherapy on time for toxicity reasons.
  • Patients With Miller-Payne (MP) Score 3, 4, or 5 Response [ Time Frame: 2 years ]
    To describe a panel of molecular assays for an association with clinical response and, if feasible, with pathologic complete response (pCR) in ER-, PR-, HER2-negative subjects treated with cisplatin and bevacizumab in the preoperative setting. A Miller-Payne (MP) score of 3 indicates a decrease in the size of the cancer by 30% to 90%. A MP score of 4 indicates marked decrease in the size of the cancer by greater than 90%. A MP score of 5 indicates there is no residual cancer remaining (the same as a pathologic complete response).
Original Secondary Outcome Measures  ICMJE
 (submitted: December 20, 2007)
  • To determine the clinical response rate, defined as the number of partial and complete responses, after preoperative therapy with cisplatin and bevacizumab in this patient population. [ Time Frame: 2 years ]
  • To determine the feasibility and toxicity of administering bevacizumab in combination with standard adjuvant chemotherapy. [ Time Frame: 2 years ]
  • To describe a panel of molecular assays for an association with clinical response and, if feasible, with pathologic complete response in ER-, PR-, HER2-negative subjects treated with cisplatin and bevacizumab in the preoperative setting. [ Time Frame: 2 years ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
Official Title  ICMJE A Phase II Trial of Preoperative Cisplatin and Bevacizumab in Estrogen Receptor (ER) Negative, Progesterone (PR) Negative, Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Brief Summary The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor (ER) negative, Progesterone Receptor (PR) negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer. Cisplatin is used to destroy cancer cells in many types of cancers, and has shown to be effective and have manageable side effects. Bevacizumab is an antibody, which is a protein that attacks a foreign substance in the body. Bevacizumab slows or stops cell growth in cancerous tumors by decreasing the blood supply to the tumors.
Detailed Description
  • To prepare for surgery, a small "clip" will be placed into the tumor area so that the surgeon can locate the site of the tumor at the time of surgery. This is a standard procedure for breast cancer.
  • The study drugs will be given in four 3-week cycles (about 3 months). Participants will come into the clinic each day they receive study treatment intravenously. Cisplatin will be given on day one of the treatment cycle (once every 3 weeks) for four cycles. Bevacizumab will be given on day one of the treatment cycle for three cycles.
  • On day one of each 3-week cycle a physical exam, routine blood tests and urine test will be performed. 7-8 days after chemotherapy, blood tests and a hearing test will be performed. A preoperative study visit will take place 7-10 days before surgery and a physical exam, routine blood tests, Electrocardiogram (EKG) and an Magnetic Resonance Imaging (MRI) of the breast will be performed.
  • Surgery to remove the tumor will occur at least three weeks after the last dose of cisplatin and is considered standard of care.
  • Postoperative chemotherapy will begin at least three weeks after surgery. Everyone on the research study will receive four 2-week cycles of doxorubicin and cyclophosphamide plus bevacizumab. After the 8 weeks, the doctor will decide which of the following two treatment regimens the participant will receive: Bevacizumab for four 2-week cycles (once every two weeks) or; Paclitaxel plus bevacizumab for four 2-week cycles (once every two weeks).
  • At the end of the postoperative chemotherapy, the participant will return to the clinic for a medical history, physical exam, vital signs, performance status, routine blood tests, multiple gated acquisition scan (MUGA) or Echocardiogram Scans, and a hearing test.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Cancer
Intervention  ICMJE
  • Drug: cisplatin
    Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
    Other Name: platinol
  • Drug: bevacizumab
    Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
    Other Name: Avastin
  • Drug: doxorubicin
    Postoperative: Given intravenously for four 2-week cycles
    Other Name: adriamycin
  • Drug: cyclophosphamide
    Postoperative: Given intravenously for four two-week cycles
    Other Name: cytoxan
  • Drug: paclitaxel
    Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
    Other Name: taxol
Study Arms  ICMJE Experimental: Cisplatin/Avastin
Cisplatin 75mg/m2 every 3 weeks, neoadjuvant bevacizumab 15mg/m2 every 3 weeks, neoadjuvant doxorubicin, adjuvant (optional) cyclophosphamide , adjuvant (optional) paclitaxel, adjuvant (optional)
Interventions:
  • Drug: cisplatin
  • Drug: bevacizumab
  • Drug: doxorubicin
  • Drug: cyclophosphamide
  • Drug: paclitaxel
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 22, 2017)
51
Original Estimated Enrollment  ICMJE
 (submitted: December 20, 2007)
40
Actual Study Completion Date  ICMJE June 2020
Actual Primary Completion Date December 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • All tumors must be ER-, PR- and HER2-negative
  • Clinical stage T2 or T3, N0-3, M0. Subjects with inflammatory breast cancer are not eligible
  • For subjects with clinically negative axilla, a sentinel lymph node biopsy will be performed either up front or after preoperative therapy at the discretion of the subject's physicians; for subjects with a clinically positive axilla, a needle aspiration or core biopsy will be performed to confirm the presence of metastatic disease in the lymph nodes.
  • 18 years of age or older
  • Performance status (PS) of 0 or 1
  • Use of an effective means of contraception in subjects of child-bearing potential
  • Normal organ function as described in the protocol

Exclusion Criteria:

  • Any prior cytotoxic chemotherapy or radiation for the current breast cancer
  • HER2-negative ipsilateral breast recurrence, unless prior treatment consisted of excision alone for ductal carcinoma in situ (DCIS)or breast-conserving treatment and hormonal therapy for DCIS or invasive cancer
  • Life expectancy of less than 12 weeks
  • Current, recent, or planned participation in an experimental durg study other than a Genentech-sponsored bevacizumab cancer study
  • Renal dysfunction for which exposure to cisplatin would require dose modifications
  • Steroid dependent asthma
  • Peripheral neuropathy of any etiology that exceeds grade 1
  • Uncontrolled diabetes
  • History of malignancy treated without curative intent
  • Any other pre-existing medical condition that would represent toxicity in excess of grade 1
  • Inadequately controlled hypertension
  • Any prior history of hypertensive crisis or hypertensive encephalopathy
  • New York Heart Association (NYHA) Grade II or greater congestive hear failure
  • History of myocardial infarction or unstable angina within 12 months prior to study enrollment
  • Any history of stroke or transient ischemic attack at any time
  • Known central nervous system (CNS) disease
  • Significant vascular disease
  • Symptomatic peripheral vascular disease
  • Evidence of bleeding diathesis or coagulopathy
  • Major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to study enrollment
  • History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months prior to study enrollment
  • Serious, non-healing wound, ulcer or bone fracture
  • Proteinuria at screening
  • Known hypersensitivity to any component of bevacizumab
  • Pregnant or lactating
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00580333
Other Study ID Numbers  ICMJE 06-202
AVF36335 ( Other Identifier: Genentech )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Steven J Isakoff, MD, PhD, Massachusetts General Hospital
Study Sponsor  ICMJE Massachusetts General Hospital
Collaborators  ICMJE
  • Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Genentech, Inc.
Investigators  ICMJE
Principal Investigator: Paula D. Ryan, MD Texas Oncology-The Woodlands
PRS Account Massachusetts General Hospital
Verification Date May 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP